Applied Translational Genetics Group, Centre for Brain Research, School of Biological Sciences, The University of Auckland, Auckland 1010, New Zealand.
Int J Mol Sci. 2023 Aug 21;24(16):13021. doi: 10.3390/ijms241613021.
Huntington's disease (HD) is a debilitating neurodegenerative genetic disorder caused by an expanded polyglutamine-coding (CAG) trinucleotide repeat in the huntingtin () gene. HD behaves as a highly penetrant dominant disorder likely acting through a toxic gain of function by the mutant huntingtin protein. Widespread cellular degeneration of the medium spiny neurons of the caudate nucleus and putamen are responsible for the onset of symptomology that encompasses motor, cognitive, and behavioural abnormalities. Over the past 150 years of HD research since George Huntington published his description, a plethora of pathogenic mechanisms have been proposed with key themes including excitotoxicity, dopaminergic imbalance, mitochondrial dysfunction, metabolic defects, disruption of proteostasis, transcriptional dysregulation, and neuroinflammation. Despite the identification and characterisation of the causative gene and mutation and significant advances in our understanding of the cellular pathology in recent years, a disease-modifying intervention has not yet been clinically approved. This review includes an overview of Huntington's disease, from its genetic aetiology to clinical presentation and its pathogenic manifestation. An updated view of molecular mechanisms and the latest therapeutic developments will also be discussed.
亨廷顿病 (HD) 是一种使人衰弱的神经退行性遗传疾病,由亨廷顿基因中扩展的多聚谷氨酰胺编码 (CAG) 三核苷酸重复序列引起。HD 表现为一种高外显率的显性疾病,可能通过突变亨廷顿蛋白的毒性功能获得而起作用。尾状核和壳核的中型多棘神经元的广泛细胞变性是导致运动、认知和行为异常等症状出现的原因。自 George Huntington 发表他的描述以来,在过去 150 年的 HD 研究中,已经提出了大量的致病机制,其中关键主题包括兴奋性毒性、多巴胺能失衡、线粒体功能障碍、代谢缺陷、蛋白质稳态破坏、转录失调和神经炎症。尽管已经确定和描述了致病基因和突变,并在近年来对细胞病理学有了重大的理解,但仍未在临床上批准一种能够改变疾病进程的干预措施。本综述包括亨廷顿病的概述,从其遗传病因到临床表现及其发病机制。还将讨论分子机制的最新观点和最新的治疗进展。